Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

Neurology

Volumn 64, Issue 1, 2005, Pages 94-101

  Bayer, A J ^a   Bullock, R ^b   Jones, R W ^c   Wilkinson, D ^d   Paterson, K R ^e   Jenkins, L ^f   Millais, S B ^g   Donoghue, S ^g  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b VICTORIA HOSPITAL   (United Kingdom)

^c St Martins Hospital   (United Kingdom)

^d MOORGREEN HOSPITAL   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f PFIZER INC   (United States)

^g Elan Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; DEXAMETHASONE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; INFLUENZA VACCINE; PARACETAMOL; POLYSORBATE 80; QS 21; RIVASTIGMINE;

ACCIDENT; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACKACHE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DEEP VEIN THROMBOSIS; DEMENTIA; DEPRESSION; DISABILITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; FOLLOW UP; GINKGO BILOBA; HALLUCINATION; HEADACHE; HOSTILITY; HUMAN; HYPERTENSION; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION; INJECTION PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MENINGOENCEPHALITIS; METABOLIC DISORDER; MULTICENTER STUDY; NUTRITIONAL DISORDER; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 11444267243     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148604.77591.67     Document Type: Article

References (23)

1. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
2. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease. BMJ 2001;323:123-124.
3. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-584.
4. Citron M, Oltersdorf T, Haass C, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360:672-674.
5. Hardy J, Duff K, Hardy KG, et al. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1998;1:355-358.
6. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994;264:1336-1340.
7. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-1495.
8. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-1491.
9. Games D, Bard F, Grajeda H, et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42. Ann NY Acad Sci 2000;920:274-284.
10. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177. Letter.
11. Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159:439-447.
12. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982. Letter.
13. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985. Letter.
14. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. World Medical Association. World Medical Association Declaration of Helsinki. 2002. Available at: http://www.wma.net/e/policy/b3.htm#paragraphe29. Accessed March 03, 2004.
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
19. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 suppl 2:S22-S32.
20. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr 1997;9 suppl 1:163-165.
21. Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54.
22. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
23. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.